Pre-Test Improving the Management of Cholangiocarcinoma: NCCN Guidelines to Improve Diagnosis, Molecular Testing, and Targeted Treatment Pre-Test Which of the following targetable biomarkers occurs in ~11% of intrahepatic cholangiocarcinomas? ERBB2 amplifications FGFR1-3 fusions and amplifications KRAS substitutions PI3KCA substitutions Unsure Which of the following is a first-in-class IDH1 inhibitor that has been approved by the FDA and recommended by the NCCN for the treatment of adults with previously treated locally advanced or metastatic cholangiocarcinoma with an IDH1 mutation? Derazantinib Entrectinib Ivosidenib Selpercatinib Unsure Which of the following agents is matched with the correct target? Derazantinib: BRAF V600E Futibatinib: RET Infigratinib: IDH1 Pemigatinib: FGFR2 Unsure Which of the following FGFR inhibitors, approved by the FDA in 2022, led to a median progression free survival of 9 months and a median overall survival of 21.7 months in FGFR2 fusion-positive cholangiocarcinoma? Derazantinib Futibatinib Infigratinib Ponatinib Unsure How confident are you in your ability to utilize current NCCN guidance and best practices for the accurate diagnosis and management of cholangiocarcinoma? Very confident Confident Somewhat confident Not very confident Not at all confident
